YOLFTbeta
Medincell SA

Medincell SA

MEDCL · PA · Healthcare / Biotechnology

28.82EUR-0.26 (-0.89%)

Price History

Full chart

Market Stats

Previous Close29.08
Open28.96
Day Range28.40 – 29.30
52-Week Range19.69 – 39.68
Volume31.55K
Market Cap797.47M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.94
Dividend Yield0.00%
Beta0.97
50-Day Avg23.80
200-Day Avg24.75

About

MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France. The company offers UZEDY, a subcutaneous risperidone for the treatment of schizophrenia. It also develops mdc-TJK, a subcutaneous injection, which is in NDA stage for the treatment of schizophrenia; and mdc-CWM, a sustained-release formulation of celecoxib, which is in Phase III clinical trial for the treatment and reduction of post-operative pain and inflammation. In addition, the company engages in the development of products in preclinical stage, including mdc-WWM for contraception; mdc-STM for the treatment of malaria; and mdc-AbbVie-1. It has strategic collaborations with TEVA, AIC, ABBVIE, Unitaid, and Gates Foundation. The company was incorporated in 2003 and is headquartered in Jacou, France.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Christophe Douat
  • Employees141
  • Headquarters3, rue des Frères Lumière, Jacou, France, 34830, France
  • Websitehttps://www.medincell.com

Leadership

  • Mr. Christophe DouatCEO & Director · b. 1966
  • Mr. Stephane PosticChief Financial Officer
  • Mr. Philippe MoyenChief Operating Officer
  • Ms. Julie AlimiGeneral Counsel & Chief Corporate Development Officer
  • Mr. David HeuzeHead of Corporate & Financial Communications and ESG
  • Mr. Franck PouzacheChief People Officer
  • Mr. Adolfo Lopez-NoriegaHead of Research & Development
  • Mr. Sebastien EnaultChief Business Officer
  • Ms. Quiterie De BeauregardHead of Global Health Development
  • Dr. Grace Kim Ph.D.Chief Strategy Officer of U.S. Finance

Financials

Income Statement

Currency: EUR2016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Total Revenue8.23M8.53M6.44M1.44M2.85M8.19M4.09M9.94M9.16M25.54M19.52M
Growth (%)-+3.66%-24.55%-77.59%+97.64%+187.03%-50.04%+143.13%-7.88%+178.83%-23.57%
Cost of Revenue332.00K885.00K218.00K1.01M969.00K1.45M-4.25M-3.77M2.79M1.15M0
Gross Profit7.90M7.65M6.22M434.00K1.88M6.74M4.09M9.94M9.16M25.54M19.52M
Gross Margin95.97%89.63%96.61%30.08%66.02%82.27%100.00%100.00%100.00%100.00%100.00%
Operating Expense7.48M11.24M13.60M15.95M21.21M22.34M27.90M33.97M30.14M36.38M45.02M
Operating Income421.00K-3.59M-7.38M-15.52M-19.32M-15.61M-23.81M-24.02M-20.98M-10.84M-25.50M
Operating Margin5.11%-42.06%-114.60%-1075.26%-677.56%-190.65%-582.25%-241.60%-229.01%-42.44%-130.63%
EBITDA788.00K-3.03M-6.41M-16.81M-18.07M-15.38M-21.45M-26.41M-18.61M-11.20M-23.67M
EBITDA Margin9.57%-35.51%-99.50%-1164.80%-633.70%-187.87%-524.35%-265.62%-203.21%-43.85%-121.27%
Net Income622.00K-3.56M-9.57M-19.69M-23.91M-19.02M-24.81M-32.01M-25.04M-18.44M-31.29M
Net Income Margin7.56%-41.73%-148.66%-1364.31%-838.53%-232.35%-606.50%-321.90%-273.34%-72.19%-160.27%
R&D5.96M7.55M8.85M11.33M17.21M18.50M23.61M27.93M21.08M24.31M26.54M
R&D as % of Total Revenue72.38%88.49%137.40%785.17%603.58%226.06%577.19%280.82%230.09%95.19%135.94%
Interest Expense127.00K1.28M1.85M2.13M2.11M2.27M1.84M3.93M4.62M5.09M6.58M
Interest Expense % of Total Revenue1.54%15.05%28.70%147.40%74.09%27.69%45.09%39.54%50.40%19.92%33.72%

Balance Sheet

Currency: EUR2016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Total Assets11.17M23.27M25.35M37.98M27.31M63.61M44.30M29.34M36.95M90.45M108.05M
Total Liabilities9.85M25.55M37.10M31.74M43.27M54.69M57.67M71.63M77.77M106.82M104.99M
Total Equity1.24M-2.33M-11.78M6.24M-15.96M8.92M-13.37M-42.29M-40.82M-16.37M3.06M
Cash636.00K3.82M8.79M21.28M12.38M47.09M24.62M6.47M19.46M59.04M62.79M
Total Debt4.32M20.70M31.00M27.04M33.84M43.34M47.49M57.71M58.96M58.76M57.41M
Net Debt3.69M16.88M22.21M5.75M21.46M-3.75M22.88M51.24M39.50M-284.00K-5.38M

Cash Flow

Currency: EUR2016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Operating Cash Flow68.00K-3.39M-5.43M-15.93M-12.54M-12.14M-21.36M-21.00M-11.92M19.46M-24.55M
Investing Cash Flow-1.49M-7.89M2.24M-832.00K72.00K-1.06M-316.00K1.30M-613.00K-13.21M-10.51M
Financing Cash Flow557.00K14.64M8.15M29.24M3.56M47.92M-800.00K1.56M25.53M33.32M38.82M
Capital Expenditure1.16M1.83M1.19M754.00K921.00K819.00K1.97M1.03M1.19M1.66M2.04M
Free Cash Flow-1.10M-5.22M-6.61M-16.69M-13.46M-12.96M-23.34M-22.03M-13.11M17.80M-26.60M
Dividends Paid-17.77M-20.30M6.62M192.00K2.45M----
FCF to OCF-1611.76%153.96%121.89%104.73%107.35%106.75%109.24%104.89%109.99%91.47%108.32%
Dividend Paid to FCF--340.16%--121.65%-49.18%-1.48%-10.50%----

Earnings

Report DateDec 3, 2018Jun 4, 2019Jul 31, 2019Dec 4, 2019Jul 29, 2020Dec 9, 2020Jul 28, 2021Dec 8, 2021Jun 14, 2022Dec 6, 2022Jun 10, 2024Aug 28, 2024Dec 10, 2024Feb 26, 2025Jun 17, 2025Jul 29, 2025Dec 9, 2025Feb 25, 2026Dec 8, 2026
EPS Estimate0.000.000.000.000.000.000.000.000.00--0.32-0.20-0.19-0.18-0.17-0.17-0.16-0.02-
EPS Actual-0.68-1.36-0.33-0.45-0.74-0.50-0.36-0.47-0.52-0.55-0.17-0.20-0.50-0.17-0.17-0.13-0.180.00-
Surprise----------46.88%0.00%-163.16%5.56%0.00%23.53%-12.50%100.00%-
Timing--------After-hoursAfter-hours----Pre-market-After-hours-Pre-market

Key Statistics & Ratios

Market Cap797.47M
Enterprise Value785.87M
Trailing P/E0.00
Forward P/E0.00
Price / Sales32.85
Price / Book265.43
EPS-0.94
Book Value0.085
Revenue (TTM)24.28M
Gross Profit (TTM)24.28M
EBITDA-20.04M
Profit Margin-128.88%
Operating Margin-139.50%
Return on Equity0.00%
Return on Assets-13.06%
Shares Outstanding35.92M
Shares Float32.79M
Beta0.97
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%